Integral Launches World’s First Stablecoin-based Crypto Prime Broker

30.9.2025 09:00:00 CEST | Business Wire | Press Release

Integral, a global leader in FX and digital asset technology, today announced the launch of PrimeOne, the world’s first stablecoin-based crypto prime brokerage. Built on the Codex Layer-1 EVM blockchain, PrimeOne delivers institutional-grade credit, trading, and net settlement in a single, integrated platform.

PrimeOne allows clients to trade with leading crypto market makers and exchanges through a single account - eliminating the need to maintain separate relationships across venues. Clients benefit from faster time to market, streamlined onboarding with just one AML/KYC check, and no credit requirement.

Unlike traditional models, PrimeOne’s on-chain infrastructure ensures clients retain control of their assets at all times. As open positions change in value, USD stablecoin-based margin automatically moves between counterparties’ wallets in real time, virtually eliminating counterparty credit risk. Trading limits are dynamically set based on margin balances held by PrimeOne participants.

The result is a complete trading ecosystem that offers superior liquidity, improved operational efficiency, and dramatically reduced capital requirements and credit exposure.

Launched at a pivotal time of accelerating institutional adoption, PrimeOne combines the resiliency of institutional-grade infrastructure with the innovations of decentralized finance. By leveraging stablecoins and real-time margin exchange, PrimeOne prevents defaults from cascading across participants - delivering a more resilient, democratized credit network.

Harpal Sandhu, CEO of Integral, commented: “As institutional adoption of crypto accelerates, the lack of accessible credit remains the last major hurdle to widespread participation. As the technology provider powering more than $1 trillion of FX trading monthly, Integral is now bringing our best-in-class infrastructure to digital assets. PrimeOne reduces risk, cost, and complexity while unlocking liquidity, profitability, and confidence in crypto trading.”

Scotte Moegling, from Virtu Financial, also said: “We are strong proponents of the emergence of the blockchain technology, and PrimeOne exemplifies the powerful democratizing capabilities that it delivers. PrimeOne will enable investors access to greater competitive pricing with less risk, unlocking significant growth potential for crypto trading on the platform.”

Peter Wisniewski, Managing Partner of Europa Partners, added: “PrimeOne is a gateway to the future of credit in cryptocurrency markets. The ease of setup, speed of onboarding, and access to liquidity will allow us to trade more profitably, more efficiently and at lower costs. This will help us deliver higher returns and capitalize on unprecedented opportunities in cryptocurrency markets.”

For more information about PrimeOne, visit primeone.net.

About Integral

Integral is the currency technology partner to hundreds of financial institutions, including banks, brokers, investors and cross-border payment companies, who have embedded Integral’s technology in their workflows and customer-facing services.

Adopted first by the financial markets and now integrated across all industries - our embedded FX and digital asset services are solving the challenges faced by every global organization.

Founded in 1993, we support customers from our offices in Palo Alto, New York, London, Tokyo, Singapore and Bengaluru.

Additional information is available at integral.com.

About PrimeOne

PrimeOne is a next-generation prime brokerage service for crypto markets. With a single account, clients can trade with any counterparty they choose. At its core, it is a breakthrough credit mechanism that transfers mark-to-market gains and losses in real time, ensuring safe and efficient trading between participants. This innovation makes PrimeOne the only truly scalable credit solution - enabling rapid client onboarding without balance sheet exposure.

Additional information is available at primeone.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250930526634/en/

Contacts

Integral, 380 Portage Avenue, Palo Alto, California 94306
email: integral@aspectusgroup.com

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom